EXAS executive Jacob Orville reports 5,000-share Rule 10b5-1 sale

Rhea-AI Filing Summary

EXACT Sciences Corp. (EXAS) executive vice president and general manager of Screening, Jacob A. Orville, reported an open‑market sale of company stock. On 11/19/2025, he sold 5,000 shares of EXAS common stock at a price of $75 per share in a transaction coded "S" for sale.

After this transaction, Orville beneficially owns 23,237 shares of common stock directly and 1,490 shares indirectly through a 401(k) plan, for a total of 24,727 common shares. In addition, he holds an aggregate of 79,661 vested and unvested stock options and restricted stock units, each RSU representing a contingent right to receive one share of common stock.

The filing notes that the reported sale was carried out under a Rule 10b5‑1 trading plan that Orville entered into on May 27, 2025, indicating the trade was made pursuant to a pre‑arranged plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ORVILLE JACOB A

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WI 53719

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GM, Screening

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/19/2025		S		5,000(1)	D	$75	23,237(2)	D
Common Stock								1,490	I	Held in 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on May 27, 2025.

2. In addition to the shares of Common Stock reported on this Form 4, which total 24,727 shares, Mr. Orville also holds, in the aggregate, an additional 79,661 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.

	/s/ Jacob A. Orville by Mark Busch, attorney-in-fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EXACT Sciences (EXAS) report for Jacob A. Orville?

On 11/19/2025, EXACT Sciences executive Jacob A. Orville reported selling 5,000 shares of EXAS common stock in an open‑market transaction coded as a sale ("S").

At what price were the EXAS shares sold in Jacob Orvilles Form 4 filing?

Jacob A. Orville sold 5,000 EXAS shares at a price of $75 per share, according to the Form 4 filing.

How many EXACT Sciences (EXAS) shares does Jacob Orville own after the reported sale?

After the sale, Jacob A. Orville beneficially owns 23,237 EXAS shares directly and 1,490 shares indirectly through a 401(k) plan, totaling 24,727 common shares.

Does Jacob Orville hold additional EXAS equity awards beyond common shares?

Yes. In addition to common shares, Jacob A. Orville holds an aggregate of 79,661 vested and unvested stock options and restricted stock units, each RSU representing one share of EXAS common stock.

Was the EXAS insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the 5,000-share sale was effected pursuant to a Rule 10b5‑1 trading plan that Jacob A. Orville entered into on May 27, 2025.

What is Jacob Orvilles role at EXACT Sciences (EXAS)?

Jacob A. Orville is identified as an officer of EXACT Sciences Corp., serving as EVP, GM, Screening in the Form 4 filing.